secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2026-10-14T11:57:03+00:00
Accession:  0001517022-26-000071
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4.1-flash:cloud@v2

Akebia Chief Commercial Officer Nicholas Grund resigns effective Nov 6; stays on as consultant
--------------------------------------------------------------------------------

- Nicholas Grund, SVP and Chief Commercial Officer, notified Akebia on Oct 7, 2026 of his resignation for personal reasons; effective Nov 6, 2026.
- Grund and the company entered into a Consulting Agreement on Oct 13, 2026, effective as of the Nov 6 resignation date.
- Consulting period runs until April 30, 2027, terminable by the company on 10 days' notice or by Grund on 30 days' notice.
- Grund will be paid an hourly rate for consulting services during the period; no successor was named in the filing.
- Filing signed by President and CEO John P. Butler on October 14, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702226000071/0001517022-26-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702226000071/akba-20261007.htm
  HTML page:      https://secwatch.observer/filing/0001517022-26-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer